Biogen announced on Tuesday that its Alzheimer’s treatment was ready to start the regulatory approval process. This with third-quarter earnings that came in above expectations had investors cheering, sending shares of the biotech stock soaring. Biogen and its Japan-based partner Eisai Co. Ltd. announced that its decision to pursue approval of aducanumab, an treatment for … Continue reading “Biogen Surprises Wall Street With This News”
